HAVE YOU RECENTLY BEEN DIAGNOSED WITH LUPUS NEPHRITIS?

Lupus Nephritis is one of the most severe forms of systemic lupus characterized by
inflammation of the kidneys. Current treatment with immunosuppressant’s and steroids
may help, but the need to find new treatments is high. If you have been diagnosed with
Lupus Nephritis, a new research study may be an option.

Centers in Canada are currently conducting a research study in people with Lupus
Nephritis to compare the effect of a new investigational drug (BI 655064) and placebo and
are looking for participants.
Qualified Participants Must:

  • Be 18 to 70 years of age
  • Be recently diagnosed with Lupus Nephritis
  • Not have acute or chronic infections including HIV, Hepatitis B or C
  • Additional Criteria may apply

Make a difference. Help us in the search for improved lupus treatments today!
To learn more about this study, please contact:

Dr. Brent Appleton
Fraser Clinical Trials
604 521-4500

Dr. Paul Fortin
Centre de recherche du CHU de Québec
CHU de Québec – Université Laval
418 525-4444 X48280

Dr. Murray Urowitz
Centre for Prognosis Studies in Rheumatic Disease – Toronto Western Hospital
416 603-5800 X3259
Further information is available at:
https://clinicaltrials.gov/ct2/show/study/NCT02770170

AVEZ-VOUS REÇU RÉCEMMENT UN DIAGNOSTIC DE NÉPHRITE LUPIQUE?

La néphrite lupique est l’une des formes de lupus disséminé les plus graves qui se caractérise par
l’inflammation des reins. Le traitement actuel par des immunodépresseurs et des stéroïdes peut
aider, mais il est grandement nécessaire de trouver de nouveaux traitements. Si vous avez reçu un
diagnostic de néphrite lupique, une nouvelle étude de recherche pourrait représenter une option.
Des centres de recherche situés au Canada mènent actuellement une étude de recherche sur la
néphrite lupique pour comparer les effets d’un nouveau médicament expérimental (BI 655064) à
ceux d’un placebo, et sont à la recherche de participants.

Les participants admissibles :

  • doivent être âgés de 18 à 70 ans;
  • doivent avoir reçu récemment un diagnostic de néphrite lupique;
  • ne doivent pas être atteints d’infections aiguës ou chroniques, notamment le VIH, l’hépatite B ou l’hépatite C;
  • des critères additionnels pourraient s’appliquer.

Faites une différence. Aidez-nous dans nos recherches visant à améliorer les traitements
contre le lupus!

Pour en savoir plus sur cette étude, veuillez communiquer avec :

Dr Brent Appleton
Fraser Clinical Trials
604-521-4500

Dr Paul Fortin
Centre de recherche du CHU de Québec
CHU de Québec – Université Laval
418-525-4444, poste 48280

Dr Murray Urowitz
Centre for Prognosis Studies in Rheumatic Disease – Toronto Western Hospital
416-603-5800, poste 3259
Vous pouvez obtenir plus de renseignements en vous rendant sur :
https://clinicaltrials.gov/ct2/show/study/NCT02770170

Blood Type Survey of Autoimmune Diseases

Along with other colleagues, Ed Harris, a Fellow from the Department of Medical Microbiology and Immunology at the University of Wisconsin, has initiated a pilot study to analyze possible associations between blood type and various autoimmune diseases. After receiving some unexpected results from an SSc survey conducted in spring of 2017, Mr. Harris has decided to expand the scope of the study to determine if this unusual blood type distribution pattern occurred in similar diseases. The study is an anonymous, two question survey (blood type and country of birth.)

They are looking at blood type distributions in five diseases:

  • Systemic Sclerosis (SSc)
  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Psoriasis
  • Ankylosing Spondylitis

SSc, SLE and RA share some similarities in their patterns including: being antinuclear antibody (ANA) positive, share some overlapping symptoms and tend to be diagnosed in middle aged women. Psoriasis and Ankylosing Spondylitis are being used as control groups and differ from the others in several factors. After getting approval for the study from the Institutional Review Board at the University, recruiting for the study has now begun.  However, due to possible research design issues that come along with self-reports, a minimum of 1000 patients are needed to complete the survey.

Who Should Take This Survey

You should complete this survey only if you have been formally diagnosed with Systemic Lupus Erythematosus (SLE).

Who Should Not Take This Survey

Patients with a tentative diagnosis such as UCTD (Undifferentiated Connective Tissue Disease).

Patients with a lupus/scleroderma overlap syndrome such as Mixed Connective Tissue Disorder (MCTD)

Note: if you wish to participate in this survey but don’t know your blood type, please call your doctor’s office to see if they have this information on file.

Depending on the initial results from the pilot study, follow-up research will be conducted using actual patient records to eliminate these self-report biases. If similar blood type distribution patterns are seen in related autoimmune diseases, this could reveal important information about the genetic basis for a broader class of autoimmune diseases. Ultimately, results from this study may help to increase understanding of autoimmune diseases and help in the quest to develop better treatments for major autoimmune diseases like SLE.

If you are living with SLE and are interested in participating in this large-scale anonymous survey of your blood type, please follow the link Survey Link: https://www.surveymonkey.com/r/8F57BC6 to complete the questionnaire.

For more information about the study http://sclerodermainfo.org/pdf/Blood-Type-Survey-Info.pdf.